The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Glycogen Synthase Kinase-3 in the Etiology and Treatment of Mood Disorders
Open accessAbstract
The mood disorders major depressive disorder and bipolar disorder are prevalent, are inadequately treated, and little is known about their etiologies. A better understanding of the causes of mood disorders would benefit from improved animal models of mood disorders, which now rely on behavioral measurements. This review considers the limitations in relating measures of rodent behaviors to mood disorders, and the evidence from behavioral assessments indicating that glycogen synthase kinase-3 (GSK3) dysregulation promotes mood disorders and is a potential target for treating mood disorders. The classical mood stabilizer lithium was identified by studying animal behaviors and later was discovered to be an inhibitor of GSK3. Several mood-relevant behavioral effects of lithium in rodents have been identified, and most have now been shown to be due to its inhibition of GSK3. An extensive variety of pharmacological and molecular approaches for manipulating GSK3 are discussed, the results of which strongly support the proposal that inhibition of GSK3 reduces both depression-like and manic-like behaviors. Studies in human postmortem brain and peripheral cells also have identified correlations between alterations in GSK3 and mood disorders. Evidence is reviewed that depression may be associated with impaired inhibitory control of GSK3, and mania by hyper-stimulation of GSK3. Taken together, these studies provide substantial support for the hypothesis that inhibition of GSK3 activity is therapeutic for mood disorders. Future research should identify the causes of dysregulated GSK3 in mood disorders and the actions of GSK3 that contribute to these diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“This is supported by findings that antidepressants (Malberg et al., 2000; Manev et al., 2001; Malberg and Duman, 2003; Santarelli et al., 2003; Warner-Schmidt and Duman, 2007; David et al., 2009) and lithium (Chen et al., 2000; Hashimoto et al., 2003; Silva et al., 2008; Wexler et al., 2008)…”
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023 · cited 1×
“This has led to measurements of behaviors, instead of mood, in rodents, although it remains unclear to what extent assessments of rodent behaviors can be useful for clarifying the causes of mood disorders and for developing new therapeutics (Chen et al., 2010; Nestler and Hyman, 2010).”
McEwen, B. S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.071 · Cited by 1,864 · cited 2×
“, 2008) increase neurogenesis in mice, and chronic stress associated with depression-like behaviors decreases neurogenesis (Malberg and Duman, 2003; Dranovsky and Hen, 2006; McEwen, 2008).”
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069 · cited 1×
“Substantial evidence indicates that mood disorders are associated with neuronal stress, such as oxidative stress and endoplasmic reticulum (ER) stress (Kato and Kato, 2000; Wang, 2007; Andreazza et al., 2008; Ng et al., 2008; Steckert et al., 2010).”
Regulation of innate immune responses in the brain
Rivest, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2565 · Cited by 843 · cited 1×
“Substantial evidence has accumulated demonstrating that mood disorders are associated with activation of the inflammatory system and other alterations of the immune system (Chourbaji et al., 2008; Dantzer et al., 2008; Miller et al., 2009; Rivest, 2009; Miller, 2010).”
Cited by
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Self-citationGSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Maes, M., Fišar, Z., Medina, M., Scapagnini, G., Nowak, G., & Berk, M. (2012) · Inflammopharmacology · doi:10.1007/s10787-011-0111-7 · Cited by 325
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
Cheng, Y., Desse, S., Martinez, A., Worthen, R. J., Jope, R. S., & Beurel, E. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.003 · Cited by 292
Self-citationInhibition of GSK3 by lithium, from single molecules to signaling networks
Freland, L., & Beaulieu, J.-M. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00014 · Cited by 269
Liu, R.-J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., & Aghajanian, G. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.128 · Cited by 256
“This inhibition can occur in two ways: directly by antagonizing Mgþþ and indirectly through activation of the serine/threonine kinase Akt upstream from mTOR (Freland and Beaulieu, 2012) and lithium destabilization of a b-arrestin/Akt/PP2A/GSK-3 complex (Jope, 2011).”
Cheng, Y., Pardo, M., Armini, R. D. S., Martinez, A., Mouhsine, H., Zagury, J.-F., Jope, R. S., & Beurel, E. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.12.012 · Cited by 174
Self-citationSepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M.-J., & Akhondzadeh, S. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.58 · Cited by 153
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
Kashani, L., Omidvar, T., Farazmand, B., Modabbernia, A., Ramzanzadeh, F., Tehraninejad, E. S., Ashrafi, M., Tabrizi, M., & Akhondzadeh, S. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.08.010 · Cited by 116
Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits
Beurel, E., & Jope, R. S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.129 · Cited by 92
“Correspondence: Professor RS Jope, Miller School of Medicine, University of Miami, 1011 NW 15th Street, Gautier Building Room 416, Miami, FL 33136, USA.”
Self-citationGSK3β: a master player in depressive disorder pathogenesis and treatment responsiveness
Duda, P., Hajka, D., Wójcicka, O., Rakus, D., & Gizak, A. (2020) · Cells · doi:10.3390/cells9030727 · Cited by 84
Beurel, E., Grieco, S. F., Amadei, C., Downey, K., & Jope, R. S. (2016) · Bipolar Disorders · doi:10.1111/bdi.12436 · Cited by 76
Self-citationFKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications
Gassen, N. C., Hartmann, J., Zannas, A. S., Kretzschmar, A., Zschocke, J., Maccarrone, G., Hafner, K., Zellner, A., Kollmannsberger, L. K., Wagner, K. V., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.38 · Cited by 62
Mao, Y., Fisher, D. W., Yang, S., Keszycki, R. M., & Dong, H. (2020) · PLOS ONE · doi:10.1371/journal.pone.0226021 · Cited by 28
Glycogen synthase kinase 3 activity enhances liver inflammation in MASH
Khoury, M., Guo, Q., Furuta, K., Correia, C., Meroueh, C., Kim Lee, H. S., Warasnhe, K., Valenzuela-Pérez, L., Mazar, A. P., Kim, I., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101073 · Cited by 17
Metadata
- Authors
- Jope, R. S.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2011
- Volume
- 4
- Pages
- 16-16
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2138681004
- Cited by
- 176
- References
- 35
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.